Stephan Stilgenbauer
Overview
Explore the profile of Stephan Stilgenbauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
424
Citations
17100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glaser S, Fischer A, Martinez-Manjon J, Lopez C, Kretzmer H, Burkhardt B, et al.
Leukemia
. 2025 Mar;
PMID: 40065077
No abstract available.
2.
Chteinberg E, Kolarova J, Vogt J, Macamo A, Bormann F, Kretzmer H, et al.
J Pathol
. 2025 Mar;
PMID: 40034069
Merkel cell carcinoma (MCC) is a highly malignant skin cancer that expresses epithelial-, neuroendocrine-, and lymphoid-associated genes. Here, we focused on B-cell differentiation, which is characterised by the coexpression of...
3.
Bundschu K, Aleksandrova-Yankulovska S, Denzer C, Dornbrach T, Eberhart S, Glisic L, et al.
J Reprod Immunol
. 2025 Feb;
168:104455.
PMID: 39970616
Reproductive health is of major importance for individuals, for the society and for the health of future generations. This includes physical and medical dimensions as well as psychosocial and ethical...
4.
Furstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, et al.
Blood
. 2025 Jan;
PMID: 39883943
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total,...
5.
Arseni L, Sigismondo G, Yazdanparast H, Hermansen J, Mack N, Ohl S, et al.
Nat Commun
. 2025 Jan;
16(1):1041.
PMID: 39863584
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model...
6.
Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland J, Brieghel C, et al.
Hemasphere
. 2025 Jan;
9(1):e70065.
PMID: 39840379
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41...
7.
Arndt V, Doege D, Frohling S, Albers P, Algul H, Bargou R, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):39.
PMID: 39825921
No abstract available.
8.
Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):37.
PMID: 39820556
Background: Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional variants of the...
9.
Tausch E, Schneider C, Stilgenbauer S
Hematology Am Soc Hematol Educ Program
. 2024 Dec;
2024(1):457-466.
PMID: 39644006
The treatment of chronic lymphocytic leukemia (CLL) has been transformed over the past decade based on a better understanding of disease biology, especially regarding molecular genetic drivers and relevant signaling...
10.
Langerbeins P, Robrecht S, Nieper P, Cramer P, Furstenau M, Al-Sawaf O, et al.
J Clin Oncol
. 2024 Nov;
43(4):392-402.
PMID: 39602678
Purpose: The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies. Methods: The German CLL Study Group conducted a randomized, double-blind,...